NORTHWEST BIOTHERAPEUTICS INC

Northwest Biotherapeutics, Inc. has entered into a Commercial Loan Agreement and Note for $5,505,000 with Streeterville Capital, LLC. The loan matures in 22 months, with principal and interest payments beginning after an initial 8-month interest-only period. Interest is set at 8% per annum, and there is a 10% original issue discount. The company has the option to pre-pay the loan, which would incur a 10% charge. Funds are intended for ongoing business operations.

Northwest Biotherapeutics (NWBO) entered into a $4.9 million convertible promissory note financing with YA II PN, Ltd. The note has a 12-month term with no interest and a 5% original issue discount, with repayment due at maturity. The company also established a standby equity subscription agreement, allowing it to require Yorkville to subscribe for up to $50 million in common shares over 24 months, exercisable after the note is repaid or converted. Additionally, Yorkville received a warrant to purchase up to $2 million in shares at $0.205 per share. The funds are intended for general corporate purposes, including its lead product and in-licensed portfolios.

Northwest Biotherapeutics addressed rumors alleging the rejection of its Marketing Authorization Application (MAA) for DCVax-L for glioblastoma by the Medicines and Healthcare Products Regulatory Agency (MHRA). The company confirmed with the MHRA that the application remains under initial regulatory review, has not been refused or withdrawn, and continues to progress. Northwest Biotherapeutics categorically refutes these false rumors, suggesting they may be linked to stock manipulation following positive Phase 3 trial data.

Northwest Biotherapeutics reported a net loss of $3.1 million for Q1 2026, a significant improvement from $19.3 million in Q1 2025. Revenues increased to $0.5 million, while operating expenses decreased. Despite these improvements, the company disclosed substantial doubt about its ability to continue as a going concern due to recurring operating losses and cash flow deficits. The Marketing Authorization Application for DCVax®-L for glioblastoma is currently under MHRA review in the U.K.

NORTHWEST BIOTHERAPEUTICS INC filed its annual report on Form 10-K for the fiscal year ended December 31, 2025. The filing disclosed that as of March 31, 2026, the company had 1,606,857,011 shares of common stock outstanding. Additionally, the aggregate market value of voting and non-voting common equity held by non-affiliates was approximately $340,239,000 as of June 30, 2025.